Latest news for Huber& Suhner (OTC:HSSKF) Stock

Huber& Suhner AG is a Switzerland-based company that manufactures and distributes electrical and optical connectivity systems and components that serve communication, transportation, aerospace, defense, testing and measurement, and industrial end markets. The company has three reportable segments such as Industry, Communication and Transportation. It generates the majority of revenue from Industry segment. Its product portfolio includes radio frequency and microwave products; fiber-optic products involving ultra-high data transmission speeds; low-frequency products such as databus, signal, and power cables; and passive components such as cables, connectors, assemblies, and antennas.

HUBER & SUHNER AG KAB ORD by HUBER & SUHNER AG KABEL-KAUTSCHUK-KUNSTSTOFFWERK HERISAU

Huber& Suhner AG

WIIM

UnitedHealth Group shares are trading lower following a now-deleted post on X from Bill Ackman stating he would short the stock.

Aurora Cannabis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) stock surged more than 45% on Wednesday morning following the release of its <a href="https://www.benzinga.com/news/earnings/25/02/43496003/aurora-cannabis-stock-jumps-on-record-breaking-q3-earnings">third-quarter fiscal 2025 earnings</a>, which revealed a substantial increase in revenue and profitability. The company reported total net revenue of CA$88.2 million ($61.74 million), up 37% year-over-year, driven largely by a 51% jump in its global medical cannabis business.
&#8220;This quarter was record-breaking for Aurora, driven by all-time highs in global medical net revenue, net income, adjusted EBITDA, and free cash flow,&#8221; said Miguel Martin, Aurora's executive chairman and CEO. The company also posted a net income of CA$31.2 million, a 282% year-over-year increase, and an adjusted EBITDA of CA$23.1 million, up 316%.
<h2 class="wp-block-heading">Cannabis Stocks Rally In Sympathy?</h2>
The strong earnings report triggered a broader rally in the cannabis sector, with several companies experiencing notable gains:
<ul>
<li>Canopy Growth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) jumped over 23%.</li>
<li>Tilray Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) climbed more than 10%.</li>
<li>Cronos Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) rose approximately 8%.</li>
</ul>
Investors appear to be reacting positively to Aurora's performance, particularly its growing international medical cannabis revenues and improved profitability.
<h2 class="wp-block-heading">Do Trade Tensions Play A Role?</h2>
Beyond earnings, another factor likely contributing to the sector-wide rally is the 30-day delay in U.S.-Canada tariffs, a move that has eased investor concerns. The Trump administration postponed the imposition of 25% tariffs on Canadian imports, providing a window for further trade negotiations. While cannabis wasn't explicitly mentioned in the tariff discussions, the broader economic impact on trade between the countries may be influencing sentiment toward Canadian cannabis companies.
As Aurora continues to expand its medical cannabis footprint globally, investors are closely watching whether the company can sustain its momentum in upcoming quarters.
Illustration made with Canva.

Cannabis

Equities

Markets

Movers

CRON

TLRY

Why Aurora Cannabis Stock Is Skyrocketing Wednesday: What About Canopy, Tilray, Cronos?

Trading Ideas

HCAI

Huachen AI Parking Management Technology Holding Shares Resumed Trade

SNAP

Snap shares are trading lower following Q4 financial results. The stock initially rose on the report but reversed on Wednesday. Wells Fargo downgraded the stock from Overweight to Equal-Weight.

B of A Securities analyst Tim Anderson maintains Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) with a Buy and lowers the price target from $118 to $112.

News

Price Target

Analyst Ratings

B of A Securities Maintains Buy on Merck & Co, Lowers Price Target to $112

<a href="https://clinicaltrials.gov/study/NCT05026177" title="https://clinicaltrials.gov/study/NCT05026177">https://clinicaltrials.gov/study/NCT05026177</a>

Biotech

General

SAVA

Cassava Sciences Terminates Simufilam REFOCUS-ALZ Alzheimer's Disease Clinical 
Trial.

IDEX shares are trading lower following mixed Q4 financial results.

Huachen AI Parking Management Technology Holding Shares Resumed Trade Then Again Halted On Circuit Breaker To The Downside

Nomura Holdings shares are trading higher following Q3 financial results.

Options

Agnico Eagle Mines Option Alert: Jan, 2026 $125 Calls at the Ask: 2000 @ $5.8 vs 639 OI; Earnings 2/13 After Close Ref=$99.08

B of A Securities analyst Steve Byrne downgrades FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) from Neutral to Underperform and lowers the price target from $61 to $48.

Downgrades

B of A Securities Downgrades FMC to Underperform, Lowers Price Target to $48

Wells Fargo analyst Chris Carey maintains Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) with a Equal-Weight and lowers the price target from $61 to $54.

MDLZ

Wells Fargo Maintains Equal-Weight on Mondelez International, Lowers Price Target to $54

TROW

T. Rowe Price shares are trading lower after the company missed Q4 earnings and revenue estimates.

LUNR

Intuitive Machines shares are trading lower after BofA Securities initiated coverage with an Underperform rating and a $16 price target.

Wells Fargo analyst Andrew Nowinski maintains Varonis Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNS#NASDAQ">VRNS</a>) with a Equal-Weight and lowers the price target from $48 to $46.

VRNS

Wells Fargo Maintains Equal-Weight on Varonis Systems, Lowers Price Target to $46

PLUT

Trading Halt: Halt status updated at 10:35:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

CDW Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDW#NASDAQ">CDW</a>) shares are trading higher after the company reported&nbsp;better-than-expected&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43490371/cdw-reports-fourth-quarter-and-full-year-2024-earnings" rel="noreferrer noopener">fourth-quarter&nbsp;results</a>.
Net sales rose 3.3% year-over-year to $5.186 billion, beating the consensus of $4.954 billion. Net sales from the Corporate segment increased 4.2% Y/Y to $2.35 billion, and the Small Business segment increased 4.4% Y/Y to $380 million.
Public segment net sales rose 6.1% Y/Y to $1.854 billion, led by higher net sales to Healthcare customers of 29.5% in the quarter. Net sales for CDW&#8217;s U.K. and Canadian operations rose 5.1% Y/Y to $607 million.
Average daily sales surged 5.0% Y/Y to $83.6 million. Gross margin contracted to 22.3% from 23.0% in the quarter.
The adjusted operating margin was 9.6% vs. 10.3% a year ago. Adjusted EPS of $2.48 beat the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $2.32</a>. 
CDW held&nbsp;$717.7 million&nbsp;in cash and equivalents as of December 2024.
Buyback: CDW Board of Directors approved a $750 million increase to its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43490558/cdw-authorizes-750-million-share-repurchase-program-increase-and-declares-quarterly-cash-dividend-" rel="noreferrer noopener">share repurchase authorization</a>.
The company declared a quarterly cash dividend of $0.625 per share (+1% vs. prior year period) payable on March 11, 2025, to all stockholders of record as of February 25, 2025.
Christine A. Leahy, chair and chief executive officer, said, &#8220;In this dynamic environment, our value proposition is stronger than ever as customers turn to CDW to help them address mission-critical IT and operational needs across the full IT solutions stack and lifecycle and guide them through their AI journey.&#8221;
&#8221;For 2025, we continue to target exceeding US IT market growth by 200 to 300 basis points. To achieve this, we will maintain our laser focus on meeting the evolving needs of our more than 250,000 customers around the globe and remaining the partner of choice for more than 1,000 leading and emerging technology brands.&#8221;&nbsp;
Investors can gain exposure to the stock via&nbsp;ProShares S&amp;P Technology Dividend Aristocrats ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/TDV#BATS">TDV</a>) and First Trust NASDAQ-100-Technology Sector Index Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTEC#NASDAQ">QTEC</a>).
Price Action: CDW shares are up 4.32% at $207.95 at the last check Wednesday. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43496003" target="_blank" rel="noreferrer noopener">Aurora Cannabis Stock Jumps On &#8216;Record-Breaking&#8217; Q3 Earnings</a></li>
</ul>
Photo via Shutterstock.

Earnings

Large Cap

Buybacks

Tech

First Trust NASDAQ-100 Technology Index Fund

QTEC

IT Company CDW Q4 Earnings: Sales Climb, AI Focus, Stock Buyback Boost & More

Arm Holdings PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) will be reporting its third-quarter earnings on Wednesday. Wall Street expects 34 cents in EPS and $946.73 million in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=ARM" target="_blank" rel="noreferrer noopener"> after market hours</a>.
The stock is up 121.37% over the past year, 26.52% YTD.
Let&#8217;s look at what the charts indicate for Arm stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/25/01/43298802/arm-china-eyes-leadership-change-ai-boom-and-us-china-chip-wars-reshape-the-industry">Arm China Eyes Leadership Change As AI Boom And US-China Relationship Reshape Industry</a>
<h2 class="wp-block-heading">ARM Stock Strongly Bullish Ahead Of Q3 Earnings</h2>
ARM stock is exhibiting strong bullish momentum, with its share price of $162.20 trading above key moving averages, including the five-day, 20-day and 50-day exponential moving averages. This sustained position signals strong buying pressure, reinforcing a positive outlook for continued bullish movement. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="626" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05091141/Screenshot-2025-02-05-at-7.36.16-PM.png" alt="" class="wp-image-767285" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05091141/Screenshot-2025-02-05-at-7.36.16-PM.png 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05091141/Screenshot-2025-02-05-at-7.36.16-PM-300x235.png 300w" sizes="(max-width: 626px) 100vw, 626px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020525&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
The eight-day, 20-day, 50-day and 200-day simple moving averages all indicate bullish signals, further confirming the stock's strength in the current trend.
Additionally, the Moving Average Convergence Divergence indicator at 5.07 supports the bullish outlook, while the Relative Strength Index at 58.20 suggests the stock is not yet overbought, leaving room for further upside. 
Investors should watch for potential resistance levels, but the overall technical setup points to continued strength in the near term.
<h2 class="wp-block-heading">Arm Analysts See 7% Upside</h2>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/ARM/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on Arm stock stands at a Buy with a price target of $139.23. Susquehanna, Barclays and Wells Fargo's latest ratings give ARM Holdings a $152.33 target, implying a 6.72% downside.
ARM Stock Price Action: Arm stock was up 2.8% to $166.75 at the time of publication Wednesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43491945/top-wall-street-forecasters-revamp-arm-holdings-price-expectations-ahead-of-q3-earnings">Top Wall Street Forecasters Revamp Arm Holdings Price Expectations Ahead Of Q3 Earnings</a></li>
</ul>
Photo: Shutterstock

Technicals

Previews

Arm Stock Surges Ahead Of Q3 Earnings As Bullish Signals Hold

Huachen AI Parking Management Technology Holding Shares Halted On Circuit Breaker

BMO Capital analyst James Thalacker maintains WEC Energy Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>) with a Market Perform and raises the price target from $95 to $100.

BMO Capital Maintains Market Perform on WEC Energy Group, Raises Price Target to $100

Huber& Suhner

Comments

Huber& Suhner

News

Latest news for Huber& Suhner (OTC:HSSKF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga